4/A: Imunon CEO Stacy Lindborg Reports Late Grant of Restricted Stock Units in Amended SEC Filing

Stacy Lindborg, CEO of Imunon, Inc., files an amended Form 4 to report a previously unreported grant of 25,000 restricted stock units (RSUs) received on September 6, 2024.

Summary

• This is an amended SEC Form 4 filing by Stacy Lindborg, President and CEO of Imunon, Inc.
• The amendment corrects an omission from a previous filing on September 10, 2024.
• The corrected filing reports the grant of 25,000 restricted stock units (RSUs) to Ms. Lindborg on September 6, 2024.
• These RSUs vest 100% on the first anniversary of the grant date and convert to common stock on a one-for-one basis upon vesting.
• The filing also includes a Power of Attorney, granting specific individuals the authority to act on Ms. Lindborg's behalf in matters related to SEC filings.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it is a routine disclosure of executive compensation. The amendment suggests a minor oversight, but it doesn't significantly impact the overall sentiment.

Positives

• The grant of RSUs aligns the CEO's interests with those of the shareholders.
• The one-year vesting period encourages continued service and performance.

Future Outlook

The document does not contain any forward-looking statements regarding the company's future performance.

Industry Context

Reporting of insider transactions is a standard practice to ensure transparency and prevent insider trading. This filing is part of the regular reporting requirements for company executives.

Stakeholder Impact

• Shareholders are informed about the compensation structure for the CEO.
• The RSU grant aligns the CEO's interests with those of the shareholders, potentially encouraging value creation.

Key Dates

Keywords

Form 4, Imunon, Stacy Lindborg, Restricted Stock Units, RSUs, SEC Filing, Beneficial Ownership, Amendment